Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform
Citizens analyst Silvan Turkcan reiterates enGene Therapeutics (NASDAQ:ENGN) from Market Perform to Market Perform.
Stocks · News reference
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman
enGene Therapeutics Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from
enGene Therapeutics Announces Virtual Key Opinion Leader Event On August 11 Covering NMIBC Treatment Landscape, Sequencing, Pricing And Reimbursement Dynamics